For Sanofi, better days loom ahead

Price controls and note ban hit 2016 performance; sales volume growth to drive earnings

Ujjval Jauhari  |  New Delhi 

The year 2016 was challenging for Sanofi India, the drug maker known for its brands such as Combiflam, vaccines and diabetes portfolio. While the drug price control impacted the company’s performance in the early part of CY2016 (follows January-December accounting year), note ban weighed on its December quarter numbers. These have led to its stock price remaining under pressure. But, as the impact fades out, analysts expect the company to report a strong rebound in revenue, profitability and thereby stock price. That’s why they are now bullish on Sanofi. After the company ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?
LOGIN

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital

For Sanofi, better days loom ahead

Price controls and note ban hit 2016 performance; sales volume growth to drive earnings

The year 2016 was challenging for Sanofi India, the drug maker known for its brands such as Combiflam, vaccines and diabetes portfolio. While the drug price control impacted the company's performance in the early part of CY2016 (follows January-December accounting year), note ban weight on its December quarter numbers. These have led to its stock price remaining under pressure. But, as the impact fades out, analysts expect the company to report a strong rebound in revenue, profitability and thereby stock price, which is why they are now bullish on Sanofi. Post the company reported its December quarter and financial year performance on Monday, analysts have strong buy recommendation on the stock. The expectations stem from the fact that despite pressure due to price control, volume growth in key brands is expected to be strong and will drive overall revenue. Also, launch of new product line extensions and exports of insulin pens will mean further gains. Analysts such as Ranjit Kapadia . The year 2016 was challenging for Sanofi India, the drug maker known for its brands such as Combiflam, vaccines and diabetes portfolio. While the drug price control impacted the company’s performance in the early part of CY2016 (follows January-December accounting year), note ban weighed on its December quarter numbers. These have led to its stock price remaining under pressure. But, as the impact fades out, analysts expect the company to report a strong rebound in revenue, profitability and thereby stock price. That’s why they are now bullish on Sanofi. After the company ... image
Business Standard
177 22